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Coating the Flu with Sticky Polymers to Look for New Drugs
In the search for eﬀective drugs against inﬂuenza,screening against viral neuraminidases (NAs) is acommon strategy. However, this ignores the actual
physical environment where the drugs function, immersed in
a thick mucus barrier at the surface of the host’s cells which
the virus must penetrate to get to the cell. Godula and co-
workers have taken on this challenge with a distinctly
innovative approach: using synthetic glycopolymers to wrap
up virus particles in a synthetic mucus barrier which may
provide a new tool to identify drugs which may be able to
prevent infection.1
The early stages of inﬂuenza A infection involve
hemagglutinins (carbohydrate binding proteins) on their
surface binding to sialic acids on the host cells. Fortunately,
our bodies have evolved a strategy to reduce this infection
mode by secreting a mucus which coats common points of
entry (such as lung or nasal passages) as it is also rich in
sialic acids. This results in the virus becoming trapped and
through the natural movement of mucus (which maybe
readers don't want to think about too much!) provides a
natural clearance route. As is typical of the constant host/
invader battle, inﬂuenza in turn produces NA (sialic acid
cleaving) enzymes to break through this barrier to enable
infection2 (as well as their later role in virus escape from
cells). Widely used drugs such as oseltamivir (to which there
are now reports of resistance3) are potent NA inhibitors but
are actually designed to treat infection by preventing release
of replicated virus, af ter infection has already occurred.
Hence, in the search for new drugs, NA screens are widely
employed, and lead compounds with low activity or that
have cross-reactivity with human NA are eliminated4 leading
to the identiﬁcation of potent antivirals with in vivo activity.5
In this issue, Godula et al. report on a new approach to
enable the impact of drugs that alter the mucus entrapment
of the inﬂuenza virus. By attaching a synthetic mucus barrier
onto the virus particle itself, the authors hope to assist in
identifying prophylactic drugs that function before virus cell
entry. To accomplish this in a typical experiment, the host
cells (or a cell line) need to be coated with human (or
animal) mucus from a fresh source. Herein lies the chal-
lenge; mucins are highly heterogeneous materials in terms of
both physical properties and chemical composition.
Synthetic glycopolymers oﬀer a convenient alternative to
natural glycoproteins as they have a macromolecular
structure and enable high valences of the glycans to be
presented and have been used for a range of applications
including synthetic mucus.6,7 Godula et al. synthesized sialic
acid rich glycopolymers with a lipid tail that could insert into
the inﬂuenza A membrane (building on previous work on
cell-inserting polymers8) generating a thick sialic acid rich
layer around the virus particle to mimic a mucus-trapped
virus, Figure 1. This tool can then enable the viral infection
assay directly onto host cells without using heterogeneous
mucus from a primary source.
This methodology could then be employed to screen for viral
entry inhibitors based on NA inhibition; if the compounds have
no activity, the viral NAs cleave the sialic acid units and infection
proceeds, Figure 2. It was seen here that known NA inhibiting
drugs functioned well in this assay (e.g., oseltamivir), but the
more interesting result came from a small number of ﬂavonoids
that were also screened. Although these have low NA activity
(μM versus nM for most antivirals), they were found to be
relatively potent viral entry inhibitors (using the modiﬁed
viruses). This observation suggests that taking into account the
Published: October 12, 2016
By attaching a synthetic mucus
barrier onto the virus particle
itself, the authors hope to assist in
identifying prophylactic drugs
that function before virus cell
entry.
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When inﬂuenza infects human cells it can get
trapped in a mucus shell. Godula and cow-
orkers mimic this process to provide a better
drug screening platform.
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mucus permeation/entrapment into screens for inﬂuenza
inhibitors could reveal new hits for preventative (prophylactic)
treatments which function before cell entry has occurredthis
is in contrast to current NA inhibiting drugs which treat
infection by preventing intracellular virus release postreplication.
A possible beneﬁt of this approach is that it might enable
the use of lower activity, but highly selective, NA inhibitors
in preventative medicine. The ﬂavonoids identiﬁed in this
work, using a hemagglutination model, supported this idea.
Of course, there are challenges to take this research
further. Key is to demonstrate whether the mucus barrier
constructed here is actually suﬃciently similar to nature’s
mucusa polymer brush on the surface of a particle will
behave diﬀerently from the gel-like mucus phase which has
complex material properties. As the rate of clearance and
turnover of the mucus is related to these properties, it is not
clear whether this assay is oversimpliﬁedas with any new
discovery.
These results also open up a new challenge to glycan-
mimetic chemists; can one make a self-enclosed barrier,
similar to the approach shown here, but with the necessary
complexity and physical properties to better reproduce the
Figure 1. Insertion of poly(3′sialyl lactose) polymer into inﬂuenza virus using a lipid anchor to generate a mucus-like nanobarrier.
Figure 2. Mucus-like nanobarriers to screen for new infection inhibitors. (A) In the absence of NA inhibitors the NA present on inﬂuenza disialylate
the polymers enabling cell infection to proceed, in analogy to when cells are coated with natural mucus; (B) addition of NA inhibitors (even with
weak NA activity) prevent desialyation and infection is inhibited; (C) snapshot of infection data showing that mM inhibitors of NAs (compared to
nM for oseltamivir) can still inhibit infection.
A possible beneﬁt of this
approach is that it might enable
the use of lower activity, but
highly selective, neuraminidase
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mucus barrier? It highlights the increasing convergence of
materials science with glycoscience to replicate the high
valancy and precise presentation associated with natural
glycans for anti-infective treatments.9 I am sure many will
take up this challenge!
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